Navigation Links
Cerecor Raises $22 Million Series A Financing
Date:4/4/2012

BALTIMORE, April 4, 2012 /PRNewswire/ -- Cerecor Inc., a biopharmaceutical company focused on the discovery, development and commercialization of prescription pharmaceuticals whose primary activity is in the human nervous system, announced today that it has raised over US$22 million in an overallotment of its January 2012 Series A preferred stock financing. The offering, which was placed with accredited investors including members of Cerecor's Board of Directors, significantly exceeded the offering maximum of US$15 million.  Maxim Group, LLC of New York, NY acted as placement agent in connection with the offering.

(Logo: http://photos.prnewswire.com/prnh/20120404/PH82224LOGO )

"The completion of this financing is an important step in bringing our lead product, FP01 for the treatment of chronic and acute cough, to the market and to support our early preclinical efforts in cognition and schizophrenia. We are delighted by the enthusiastic response to our offering, as it confirms the quality of our Company, its product pipeline and our founding team," stated Blake M. Paterson, M.D., Co-founder & CEO of Cerecor.

About Cerecor Inc.

Cerecor Inc. ("Cerecor" or the "Company") is a biopharmaceutical company focused on the discovery, development and commercialization of prescription pharmaceuticals whose primary activity is in the human nervous system. Cerecor is focused on translational medicine -- the accelerated transfer of technology from the academic laboratory to early human trials, with the goal of rapid commercialization. www.cerecor.com  

For More Information, contact:
John Dierkes
Kennedy Advisors
john@kennedyadvice.com 
(410) 935-9334


'/>"/>
SOURCE Cerecor Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Biotech Firm Spun Off from Childrens Hospital Raises $7 Million to Advance Magnetic-Based Vascular Treatment
2. Cowen Healthcare Royalty Partners Raises $1 Billion
3. Avaxia Biologics, Inc. Raises $2.2 Million in First Closing of Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease
4. DLVR Therapeutics Inc. Raises Additional Capital Adding MaRS Innovation to Investor Base
5. Cleave Biosciences Raises $42 Million in Series A Financing for Novel Cancer Therapies
6. Dyadic International Raises $3 Million in Private Placement of Convertible Notes
7. Creabilis Raises €15M ($20M) in Series B Fundraising Round
8. SironRX Therapeutics Raises $3.4 Million Series A
9. PPTA Praises Legislation That Protects the Treatment of Rare Diseases
10. Evergreen Foundation Gala Raises $1.16 Million for Cancer Care, Kicks off Capital Campaign
11. FireFly® Toothbrush Facebook Campaign Raises Funds for Smile Train
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... ... 2017 , ... National executive search firm, Slone Partners, announces ... and biomarker expertise, as VP of Scientific Affairs at Cambridge Biomedical. , ... development and sample testing services. The organization acts as a leading provider of ...
(Date:6/19/2017)... ... June 19, 2017 , ... As Vice ... EDETEK’s products including training, implementation, support, and client process and SOP development. , ... has previously held leadership roles for service providers and top-tier pharmaceuticals, and as ...
(Date:6/19/2017)... ... June 19, 2017 , ... A colony of healthy honey bees ... tissues by delivering pollen and nectar containing nutrients necessary for growth and survival. Better ... , Many recent indicators point to a decline in honey bee health. Sick and ...
(Date:6/16/2017)... ... June 16, 2017 , ... CTNext , Connecticut’s go-to resource for entrepreneurial ... The LOFT at Chelsea Piers in Stamford. , Nine finalists, all of whom are ... for an opportunity to secure $10,000 awards to help support business growth. The winners ...
Breaking Biology Technology:
(Date:4/3/2017)... WASHINGTON , April 3, 2017 /PRNewswire-USNewswire/ ... single-cell precision engineering platform, detected a statistically ... cell product prior to treatment and objective ... highlight the potential to predict whether cancer ... prior to treatment, as well as to ...
(Date:3/28/2017)... -- The report "Video Surveillance Market by ... Devices), Software (Video Analytics, VMS), and Service (VSaaS, Installation ... 2022", published by MarketsandMarkets, the market was valued at ... reach USD 75.64 Billion by 2022, at a CAGR ... considered for the study is 2016 and the forecast ...
(Date:3/23/2017)... 2017 Research and Markets has announced the ... Trends - Industry Forecast to 2025" report to their offering. ... The Global ... of around 8.8% over the next decade to reach approximately $14.21 ... market estimates and forecasts for all the given segments on global ...
Breaking Biology News(10 mins):